In this episode, Nathan Radcliffe, MD, discusses the widespread use of benzalkonium chloride (BAK) in the US ophthalmic market. Dr. Radcliffe acknowledges concerns about its long-term effects, such as exacerbating dry eye and impacting the success of incisional glaucoma surgery. Preservative-free formulations are favored in Europe, and Dr. Radcliffe highlights the growing recognition among US eye care clinicians regarding the need for BAK alternatives.

This activity is supported by an independent medical education grant from Théa Pharma.